

Information for Connecticut Prescribers of Prescription Drugs

ABRILADA™ (adalimumab-afzb) injection, for subcutaneous use

The prices listed below are Wholesale Acquisition Costs ("WAC"), which represent Pfizer's published list prices for the products sold to wholesalers, before any discount, rebate, or other price reduction. The price paid by consumers may be higher or lower than the prices listed below. Information about the WAC of this drug is being provided to Connecticut prescribers pursuant to Connecticut law, to give prescribers information about the WAC price of marketed drugs as well as generic drugs in the same therapeutic class.

| Marketed Product*: | WAC Package | Package Size |
|---|--------------------|---------------------|
| ABRILADA 20 mg/0.4 mL Prefilled Syringe | \$1,038.00 | 2 |
| ABRILADA 40 mg/0.8 mL Prefilled Syringe | \$1,038.00 | 2 |
| ABRILADA 40 mg/0.8 mL Prefilled Pen | \$1,038.00 | 2 |
| ABRILADA 40 mg/0.8 mL Prefilled Pen | \$519.00 | 1 |

*Prices shown are for the lowest dosage of the product.

This information is being provided pursuant to CT House Bill 6669. The information is accurate as of March 10, 2026.

The prices listed are WAC prices, which represent Pfizer's published list prices for the products sold to wholesalers, before any discount, rebate, or other price reduction. The WAC prices listed may differ significantly from actual prices paid by customers and consumers. In addition, a product's WAC is typically not associated with per-dose pricing, and does not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness of all the products listed.

Pricing information listed does not imply safety or efficacy of the product, and no comparisons should be made. For additional drug and price information see: <http://www.pfizer.com/ctprescribers>

Data as of: 10-Mar-2026